This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Should You Invest in Tenet (THC) Based on Bullish Wall Street Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Tenet Healthcare (THC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is It Worth Investing in Tenet (THC) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is Tenet Healthcare (THC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Tenet (THC)
Tenet (THC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is the Options Market Predicting a Spike in Tenet Healthcare Stock?
Investors need to pay close attention to THC stock based on the movements in the options market lately.
Tenet Healthcare Continues To Win In Q2, But Medicaid Cuts May Threaten Growth Beyond 2026
Tenet Healthcare remains a buy, consistently beating earnings and raising guidance, even as the healthcare sector faces broad pressure from looming Medicaid cuts. Ambulatory segment growth is key, as it is higher margin and less exposed to Medicaid risk than the hospital segment, which faces headwinds post-2026. Medicaid cuts are now law and will hit hardest after 2026, posing significant long-term risk to hospital revenues despite Tenet's restructuring efforts.
Tenet Healthcare Corporation (THC) Q2 2025 Earnings Call Transcript
Tenet Healthcare Corporation (NYSE:THC ) Q2 2025 Earnings Conference Call July 22, 2025 10:00 AM ET Company Participants William McDowell - Vice President of Investor Relations Saumya Sutaria - Chairman & CEO Sun Park - Executive VP & CFO Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Joshua Raskin - Nephron Research LLC Andrew Mok - Barclays Bank PLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Justin Lake - Wolfe Research, LLC Sarah James - Cantor Fitzgerald & Co., Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Ryan Langston - TD Cowen, Research Division John Ransom - Raymond James & Associates, Inc., Research Division Kevin Fischbeck - BofA Securities, Research Division Operator Good morning. Welcome to Tenet Healthcare Second Quarter 2025 Earnings Conference Call.
